Peter Attia MD276 ‒ Special episode: Peter on longevity, supplements, protein, fasting, apoB, statins, & more
At a glance
WHAT IT’S REALLY ABOUT
Peter Attia answers listener questions on longevity, supplements, lipids, nutrition, and wearables
- Attia says he sees no evidence that aging can currently be reversed, so he is skeptical of living to 120 or beyond and argues people should use today's prevention tools and focus on compressing late-life frailty.
- He explains that geroprotective interventions are hard to evaluate because there are no aging biomarkers, and he uses a risk/reward matrix (gold coin or penny, train or tricycle) to judge supplements and drugs.
- He details his current supplement stack and lipid-lowering drugs (Repatha and Nexlizet), targeting an apoB of 30 to 40 mg/dL, and explains why he favors low-dose statins when they are used.
- On nutrition, he stresses energy balance and sustainability over diet tribes, rejects the 'good vs. bad cholesterol' framing, supports high protein before age 50, and explains why he stopped prolonged fasts.
- He describes the wearables he uses and favors, including Morpheus for zone 2 training, CGMs for patients, and the Aktiia cuffless blood pressure bracelet, which is sold in Europe but not yet FDA approved.
IDEAS WORTH REMEMBERING
5 ideasAging reversal isn't on the near-term horizon
Attia says there's no evidence we can erase the diseases or underlying processes of aging, and that the gap between actual science and press or social media portrayals is enormous.
Focus on compressing late-life morbidity
Rather than chasing extreme lifespans, Attia wants people to stay physically and cognitively capable during their last decade, the 'marginal decade', which is what the centenarian decathlon is meant to train for.
Without a biomarker you can't tell if a geroprotective intervention works
Attia contrasts drugs like lisinopril, where blood pressure gives feedback, with geroprotection, where there's no way to know if you're taking too much or too little; his own long fasting regimen cost him about twenty pounds of muscle with no known benefit.
Use a risk/reward matrix for supplements
Attia places interventions on a grid of risk versus reward, such as a penny or gold coin in front of a tricycle or a train, and says he'll reevaluate any supplement when new data emerges.
ApoB can be driven very low with modern drugs
Attia says nutrition has a modest effect and pharmacology is far more potent; his baseline apoB would be 90 to 100 mg/dL, and he uses Repatha plus Nexlizet to reach a target of 30 to 40, and notes statins reach most of their effect at low doses.
WORDS WORTH SAVING
5 quotesI think it would motivate you to be more serious about using the tools that we have today for primary and secondary prevention of disease, for optimizing and maximizing, uh, lifespan and healthspan.
— Peter Attia
I think most people would rather live to ninety and, you know, die of a heart attack while swimming in the ocean, but being, you know, otherwise in remarkable shape than live to one twenty and spend the last thirty years of that unable to do much.
— Peter Attia
I always think people are majoring in the minor and minoring in the major on nutrition when they start to fight in dietary tribes on this stuff.
— Peter Attia
It's better to have a seven out of 10 diet in terms of quality and perfection that you can sustain indefinitely than a 10 out of 10 diet that you can only sustain for three or six months.
— Peter Attia
The same molecule of cholesterol inside the HDL is present inside the LDL.
— Peter Attia
High quality AI-generated summary created from speaker-labeled transcript.
